234 related articles for article (PubMed ID: 26152595)
1. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.
Møller HE; Preiss BS; Pedersen P; Kristensen IB; Hansen CT; Frederiksen M; Abildgaard N; Møller MB
APMIS; 2015 Aug; 123(8):652-8. PubMed ID: 26152595
[TBL] [Abstract][Full Text] [Related]
2. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetics of multiple myeloma.
Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
[TBL] [Abstract][Full Text] [Related]
4. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
[TBL] [Abstract][Full Text] [Related]
5. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
[TBL] [Abstract][Full Text] [Related]
8. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
[TBL] [Abstract][Full Text] [Related]
9. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
[TBL] [Abstract][Full Text] [Related]
10. Plasmablastic transformation of multiple myeloma.
Lee CK; Ma ES; Shek TW; Lam CC; Au WY; Wan TS; Chan LC
Hum Pathol; 2003 Jul; 34(7):710-4. PubMed ID: 12874768
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
12. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of Monosomies in Patients With Multiple Myeloma.
Shin SY; Eom HS; Sohn JY; Lee H; Park B; Joo J; Jang JH; Lee MN; Kim JK; Kong SY
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):159-164.e2. PubMed ID: 28089441
[TBL] [Abstract][Full Text] [Related]
14. Combined cytogenetic testing and fluorescence in situ hybridization analysis in the study of chronic lymphocytic leukemia and multiple myeloma.
Wiktor A; Van Dyke DL
Cancer Genet Cytogenet; 2004 Aug; 153(1):73-6. PubMed ID: 15325099
[TBL] [Abstract][Full Text] [Related]
15. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
16. Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma.
Mincherton TI; Lam SJ; Clarke SE; Hui HYL; Malherbe JAJ; Chuah HS; Sidiqi MH; Fuller KA; Erber WN
Int J Lab Hematol; 2024 Jun; 46(3):495-502. PubMed ID: 38379463
[TBL] [Abstract][Full Text] [Related]
17. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
18. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
19. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
[TBL] [Abstract][Full Text] [Related]
20. Detection of 14q32 rearrangements in multiple myeloma, using simultaneous FISH analysis combined with immunofluorescence.
Abaza HM; Youssef SR; Saad AA; Kamal GM; Hegazy MG; Ibrahim RI; Annaka LM
Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):56-63. PubMed ID: 25929730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
